Skip to main content

Table 1 Patient demographics

From: Patient-reported outcomes following primary total hip arthroplasty in Crowe type III or IV developmental dysplasia are comparable to those in Crowe type I: a case-control study of 96 hips with intermediate-term follow-up

 H group (n = 32 hips)Control (n = 64 hips)P-valueFO group (n = 15 hips)N-FO group (n = 15 hips)P-value
Number of patients23461012
Sex (male/female)2/214/420.6862/80/120.195
Unilateral/bilateral14/928/181.0005/59/30.221
Age (years)65.3 ± 6.364.5 ± 8.40.86469.3 ± 4.560.8 ± 6.20.002
Height (cm)146.1 ± 6.5157.3 ± 10.4<0.001142.8 ± 6.4150.6 ± 5.40.007
Weight (kg)47.9 ± 8.258.2 ± 12.4<0.00148.0 ± 12.048.8 ± 7.10.849
BMI (kg/m2)22.0 ± 3.423.5 ± 3.20.20223.5 ± 5.421.5 ± 2.80.284
Diagnosis (number of hips)
 Dysplasia31640.33314150.500
 Other100.333100.500
Average follow-up period (years)5.8 ± 2.65.4 ± 2.40.5575.4 ± 2.86.3 ± 2.80.443
Intraoperative blood loss (mL)465.9 ± 295.6245.5 ± 143.0<0.001596.0 ± 363.9355.0 ± 212.10.067
Surgery time (min)252.4 ± 108.0149.5 ± 28.3<0.001350.0 ± 124.4177.7 ± 42.80.002
LLD-preoperative (mm)24.9 ± 13.98.1 ± 5.6<0.00131.9 ± 16.018.4 ± 10.00.026
LLD-postoperative (mm)9.4 ± 7.73.0 ± 2.10.04112.5 ± 9.47.5 ± 5.60.140
Complications
 Infection200.109020.286
 Dislocation110.716100.455
 Intraoperative fracture010.53600
Preoperative JOA score (points)
 Pain15.5 ± 7.016.1 ± 6.50.67015.7 ± 7.916.0 ± 6.10.903
 ROM10.8 ± 4.712.4 ± 4.00.08112.4 ± 5.29.4 ± 3.60.056
 Gait8.4 ± 2.99.3 ± 3.40.2428.0 ± 2.59.9 ± 3.30.559
 ADL10.9 ± 3.911.3 ± 3.50.64110.8 ± 4.311.1 ± 3.60.931
 Total45.8 ± 11.149.3 ± 10.60.13947.1 ± 12.045.2 ± 10.40.579
Postoperative JOA score (points)
 Pain37.2 ± 3.037.7 ± 3.30.43937.23 ± 3.137.3 ± 3.11.000
 ROM17.4 ± 2.618.0 ± 2.60.30917.1 ± 3.317.7 ± 1.80.596
 Gait16.6 ± 3.817.6 ± 3.00.19115.8 ± 5.017.7 ± 2.20.330
 ADL16.3 ± 4.117.6 ± 2.70.09615.5 ± 4.817.1 ± 3.40.314
 Total87.4 ± 9.190.8 ± 8.70.08085.7 ± 10.589.2 ± 7.70.327
Postoperative SF-36 (points)
 PF73.3 ± 19.770.1 ± 22.30.56875.0 ± 14.771.7 ± 24.10.696
 RP81.3 ± 19.879.2 ± 24.20.72882.9 ± 16.879.7 ± 22.90.705
 BP72.0 ± 22.563.6 ± 23.20.15871.0 ± 21.572.9 ± 24.40.844
 GH59.2 ± 19.360.5 ± 16.70.78059.2 ± 19.360.5 ± 16.70.624
 VT66.6 ± 19.065.9 ± 15.40.87568.8 ± 18.364.6 ± 20.20.610
 SF88.6 ± 18.887.2 ± 17.00.76389.8 ± 9.487.5 ± 25.00.780
 RE83.0 ± 21.283.0 ± 21.31.00086.4 ± 20.279.9 ± 22.60.477
 MH72.2 ± 20.777.5 ± 15.10.22871.4 ± 21.872.9 ± 20.60.862
  1. The control group included 46 patients (64 hips) who underwent primary THA for Crowe I dysplasia, matched for age, sex, BMI, and surgical approach
  2. Values are expressed as means ± SD or as numbers (n). P-values in bold indicate statistical significance (P < 0.05)
  3. H group high hip dislocation group, FO group femoral shortening osteotomy group, N-FO group non-femoral shortening osteotomy group, THA total hip arthroplasty, BMI body mass index, LLD leg length discrepancy, JOA Japanese Orthopaedic Association, ROM range of motion, ADL activities of daily living, SF-36 Short form-36, PF Physical Functioning, RP Role Physical, BP Bodily Pain, GH General Health, VT Vitality, SF Social Functioning, RE Role Emotional, MH Mental Health, SD standard deviation